HOUSTON--(BUSINESS WIRE)--Houston-based Halsa Pharmaceuticals, Inc., has been awarded a second payment of $750,000 from the Texas Emerging Technology Fund (ETF). The Company achieved a critical milestone based on its preclinical advancement of its lead therapeutic treatment for obesity and its new manufacturing capabilities.
